Use of classifiers to optimise the identification and characterisation of metastatic breast cancer in a nationwide administrative registry
Antonios Valachis(Örebro University Hospital), Henrik Lindman(Uppsala University), Barbro Holm(Novartis (Sweden)), Máté Szilcz(Karolinska Institutet), Simona Vertuani(Novartis (Sweden)), Jonatan Freilich(Umeå University), P. Carlqvist
Cited by 21
Related Papers
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CT
|Theranostics|2015|269
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the <sup>111</sup>In-ABY-025 Affibody Molecule
|Journal of Nuclear Medicine|2014|260